CCAT2

Summary

CCAT2 (colon cancer associated transcript 2, HGNC:47044) is a long non-coding RNA gene on chromosome 8q24.21.

This gene produces a long non-coding RNA that is upregulated in colon cancer and other cancers. This transcript promotes cell proliferation and suppresses apoptosis. It negatively regulates the biogenesis of microRNA 145.

Source: NCBI Gene 101805488 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:47044
Approved symbol	CCAT2
Name	colon cancer associated transcript 2
Location	8q24.21
Locus type	RNA, long non-coding
Status	Approved
Aliases	NCCP1, LINC00873
Ensembl gene	ENSG00000280997
Ensembl biotype	lncRNA
OMIM	619403
Entrez	101805488
RNAcentral	URS000010576B — lncRNA, 1752 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 lncRNA

ENST00000630920

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000630920 — 1 exons

Exon	Start	End
ENSE00003771608	127400399	127402150

Expression profiles

Bgee: expression breadth broad, 46 present calls, max score 89.77.

Top tissues by expression

46 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.77	silver quality
bone marrow cell	CL:0002092	66.74	silver quality
tonsil	UBERON:0002372	61.37	silver quality
monocyte	CL:0000576	57.76	gold quality
blood	UBERON:0000178	52.35	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	49.29	silver quality
endometrium	UBERON:0001295	48.47	silver quality
heart left ventricle	UBERON:0002084	48.17	gold quality
lymph node	UBERON:0000029	47.91	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	47.42	gold quality
cortex of kidney	UBERON:0001225	47.32	silver quality
adrenal tissue	UBERON:0018303	47.29	silver quality
islet of Langerhans	UBERON:0000006	47.04	silver quality
right lobe of thyroid gland	UBERON:0001119	46.52	silver quality
urinary bladder	UBERON:0001255	45.41	silver quality
heart	UBERON:0000948	44.73	silver quality
gall bladder	UBERON:0002110	44.17	silver quality
adrenal gland	UBERON:0002369	43.61	silver quality
multicellular organism	UBERON:0000468	43.32	silver quality
vagina	UBERON:0000996	43.25	silver quality
tibial artery	UBERON:0007610	42.65	silver quality
thyroid gland	UBERON:0002046	42.50	silver quality
thoracic mammary gland	UBERON:0005200	42.38	silver quality
saliva-secreting gland	UBERON:0001044	42.12	gold quality
corpus callosum	UBERON:0002336	41.73	silver quality
esophagus mucosa	UBERON:0002469	41.42	silver quality
prostate gland	UBERON:0002367	41.19	silver quality
skin of abdomen	UBERON:0001416	40.58	silver quality
right atrium auricular region	UBERON:0006631	40.46	silver quality
body of uterus	UBERON:0009853	40.40	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.96

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• CCAT2 physical interaction with TCF7L2 results in an enhancement of WNT signaling. (PMID:23796952)
• findings indicate that CCAT2 is a lung adenocarcinoma-specific lncRNA and promotes invasion of non-small cell lung cancer and highlight its potential as a biomarker for lymph node metastases (PMID:24504682)
• we firstly characterized the expression profile of CCAT2 in ESCC and evaluated its potential diagnostic value as a biomarker. (PMID:25677908)
• Our results suggested that up-regulation of lncRNA CCAT2 was correlated with gastric cancer progression (PMID:25755774)
• Elevated expression of CCAT2 is associated with esophageal squamous cell carcinoma. (PMID:25919911)
• lncRNA CCAT2 was up-regulated in cervical squamous cell cancer tissues compared to the adjacent non-tumor tissues. In addition, the high CCAT2 expression was associated with the FIGO stage, lymph node metastasis and depth of cervical invasion (PMID:26722527)
• Study demonstrates that the lncRNA, CCAT2, modulates cellular energy metabolism in an allele-specific manner by interacting with the Cleavage Factor I (CFIm) complex to regulate the alternative splicing of GLS gene. (PMID:26853146)
• Long Non-Coding RNA CCAT2 promoted the proliferation and survival of cervical cancer cells. (PMID:26983975)
• we found that CCAT2 was upregulated in bladder cancer tissues and cell lines (PMID:27015551)
• CCAT2 serves as an oncogenic lncRNA, and an independent unfavorable prognostic factor in small cell lung cancer patients. (PMID:27470400)
• In conclusion, our data suggested that lncRNA CCAT2 was a novel molecule involved in PCa progression, which provided a potential prognostic biomarker and therapeutic target for new therapies in patients with prostate cancer. (PMID:27558961)
• The present study demonstrates that tamoxifen (TAM)-resistant cells show a higher level of CCAT2 expression compared with TAM-sensitive cells. Biologically, CCAT2 knockdown could inhibit proliferation and induce apoptosis in TAM-resistant cells exposed to TAM. (PMID:27830684)
• CCAT2 was up-regulated in glioma tissues and significantly correlated with the advanced tumor stage. Knockdown of CCAT2 could inhibit proliferation, cell cycle progression and migration of glioma cells. (PMID:27833083)
• CCAT2 expression in colorectal cancer tissue was significantly higher than in noncancer tissue (p < 0.001), particularly in cases of metastatic cancer (p < 0.001). Relative CCAT2 expression levels and rs6983267 genotypes were not correlated with clinicopathological features. (PMID:27875818)
• CCAT2 plays an important role in glioma tumorigenesis and progression.CCAT2 expression levels were higher in glioma than adjacent normal tissues. (PMID:27938499)
• CCAT2 promotes tumorigenesis by over-expression of Pokemon. (PMID:28088736)
• meta-analysis demonstrated that high CCAT2 expression significantly predicts poor OS, poor PFS, LNM, DM and tumor stage, suggesting that high CCAT2 expression may serve as a novel biomarker for poor prognosis and metastasis in cancers. (PMID:28089750)
• REVIEW: summary of current literature concerning the expression and functional role of CCAT2 in human malignancies (PMID:28244168)
• CCAT2 may be a potential novel biomarker for indicating clinical outcomes of human cancers (PMID:28263738)
• CCAT2 suppressed the p15 expression level via interacting with EZH2 in breast cancer cells. (PMID:28531944)
• our findings illustrate that CCAT2 acts as competing endogenous RNA (ceRNA) or sponge via negatively targeting miR-424, providing a novel diagnostic marker and therapeutic target for EOC. (PMID:28550684)
• Overall analyses showed that increased CCAT2 expression was associated with a higher risk of lymph node metastasis (LNM), an increased potential for distant metastasis (DM) and higher clinical stage (p<0.001 for LNM, p = 0.001 for DM, p<0.001 for clinical stage). (PMID:28623646)
• our results revealed a new exosomemediated mechanism by which glioma cells could promote angiogenesis through the transfer of linc-CCAT2 by exosomes to endothelial cells. Moreover, we suggest that exosomes and linc-CCAT2 are putative therapeutic targets in glioma (PMID:28656228)
• Our results showed that CCAT2 functioning as a potential oncogene was upregulated in oral squamous cell carcinoma. CCAT2 with high expression level was correlated with poor differentiation, higher T stage, and clinical stage, which made CCAT2 to be a prognostic biomarker in oral squamous cell carcinoma. (PMID:28671055)
• these results indicated that CCAT2 may play a critical role in ccRCC progression and will be further considered as a biomarker for predicting the survival of Clear cell renal cell carcinoma (ccRCC) patients and a potential therapeutic target for ccRCC intervention (PMID:28718366)
• High expression of CCAT1 and CCAT2 significantly associates with poor RFS and OS. The expression of these two lncRNAs independently, or in combination, serves as important prognostic biomarkers in CRC (PMID:28838211)
• Our results identify CCAT2 as a negative regulator of miRNA-145 biogenesis, and expose a novel mechanism of lncRNA-miRNA crosstalk (PMID:28964256)
• CCAT2 is an oncogenic lncRNA in pancreatic ductal adenocarcinoma likely regulated by the KRAS-MEK/ERK pathway. It could be a potential diagnostic biomarker and therapeutic target for pancreatic ductal adenocarcinoma. (PMID:29298720)
• lncRNA CCAT2 played an oncogenic role in Cholangiocarcinoma. (PMID:29329034)
• Upregulation of long noncoding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma (PMID:29393466)
• CCAT2 served as an oncogene in osteosarcoma and promoted osteosarcoma cell proliferation, cell cycle and invasion. (PMID:29502343)
• G variant of rs6983267 single nucleotide polymorphism (SNP) in CCAT2 gene and MYC enhancer region functions as an independent risk factor for cervical squamous cell carcinoma (SCC). MYC transcript levels are increased in cancerous and normal tissue in carriers of GG polymorphism compared with carriers of TT polymorphism (PMID:29525942)
• Our findings provide fundamental insights into the functional role of rs6983267 SNP and CCAT2 in myeloid malignancies. (PMID:29567676)
• Levels of CCAT2 expression were significantly over-expressed in colorectal cancer (CRC) tissues compared to adjacent non-tumorous tissues; higher CCAT2 expression was associated with advanced CRC patients (PMID:30877883)
• CCAT2 acts as an oncogene by up-regulating NDRG1. (PMID:30922920)
• rs6983267G allele might contribute to a decreased risk of recurrent miscarriage in the South Chinese population (PMID:30982978)
• carriers of rs6983267 GG in CCAT2 were more susceptible to hepatocellular carcinoma, with the odds ratio (OR) and adjusted odds ratio (AOR) being 1.532 (95% CI, 1.103-2.129; p = 0.011) and 1.627 (95% CI, 1.120-2.265; p = 0.033), respectively. (PMID:31398859)
• Long non-coding RNA CCAT2 was upregulated in hepatocellular carcinoma (HCC) tissues, and higher level of CCAT2 was found in advanced HCC. Long non-coding RNA CCAT2 may serve as a potential biomarker for predicting poorer prognosis in patients with hepatocellular carcinoma. (PMID:31626095)
• lncRNA CCAT2 promotes radiotherapy resistance for human esophageal carcinoma cells via the miR145/p70S6K1 and p53 pathway. (PMID:31789385)
• Long non-coding RNA CCAT2 promotes oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells. (PMID:31904506)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.